IP Library Granted Patent US 11,549,100
Granted Patent B2
US 11,549,100 · App. 16/494,273 · Granted Jan 10, 2023

Three-dimensional culture of primary cancer cells using tumor tissue

Inventors: Hideaki Kakinuma (Tokyo, JP); Yukiko Shimada (Tokyo, JP); Hiroaki Inoue (Tokyo, JP); Takashi Morikawa (Tokyo, JP)
Assignee: LSI MEDIENCE CORPORATION
C12N5/0693G01N33/5011C12N2513/00C12N2533/10C12N2533/52C12N2533/54C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,549,100
App. No.
16/494,273
Granted
Jan 10, 2023
Kind
B2
Abstract

A method of producing a cell mass by three-dimensional culture of primary cancer cells having proliferative ability and properties of handleability, versatility, and high-throughput performance, in which a tumor tissue is used as a starting material, proliferation of cells such as fibroblasts other than cancer cells is inhibited, and the cell mass includes primary cancer cells as a main component. The object is achieved by providing a method of producing a cell mass by three-dimensional culture of primary cancer cells using a tumor tissue, including: a three-dimensional culture step of culturing cells obtained from the tumor tissue in a medium containing a 5% v/v or less extracellular matrix on a substantially low-adhesive cell culture substrate.

Claims (16)

1. A method of producing a cell mass by three-dimensional culture of primary cancer cells using a tumor tissue, comprising:

culturing cells obtained from the tumor tissue in a medium containing a 5% v/v or less extracellular matrix on a substantially low-adhesive cell culture substrate, and

producing the cell mass of the primary cancer cells.

2. The method according to claim 1 , wherein the tumor tissue is a xenograft tumor.

3. The method according to claim 1 , wherein said extracellular matrix is selected from the group consisting of collagen I, collagen IV, fibronectin, laminin, vitronectin, entactin, gelatin, elastin, proteoglycan, glucosaminoglycan, chondroitin sulfate, dermatan sulfate, heparan sulfate, heparin, and keratan sulfate.

4. The method according to claim 1 , wherein the cell mass obtained by the method has an average diameter of 100 μm or more.

5. The method according to claim 1 , wherein the substantially low-adhesive cell culture substrate is a culture substrate having a hydrophilic surface or a cell culture substrate having a surface treated with a hydrophilic compound.

6. The method according to claim 1 , wherein said medium contains 0.1% v/v to 5% v/v of extracellular matrix.

7. The method according to claim 1 , wherein said three-dimensional culture step is performed from 2 days to 30 days.

8. The method according to claim 1 , wherein said medium is in a sol state.

9. The method according to claim 1 , wherein the cell mass has an average diameter of between 100 μm and 300 μm.

10. The method according to claim 1 , wherein said medium contains 0.2% v/v to 5% v/v of extracellular matrix.

11. The method according to claim 1 , wherein said medium contains 0.5% v/v to 5% v/v of extracellular matrix.

12. A kit of producing a cell mass by three-dimensional culture of primary cancer cells using a tumor tissue, comprising:

a substantially low-adhesive cell culture substrate; and

a medium containing a 5% v/v or less extracellular matrix for a three-dimensional culture step.

Assignments (4)
CHANGE OF ADDRESS Recorded Mar 6, 2024
From: LSI MEDIENCE CORPORATION
To: LSI MEDIENCE CORPORATION
Reel/Frame 066747/0488 →
COMPANY SPLIT/DE-MERGER Recorded Mar 6, 2024
From: LSI MEDIENCE CORPORATION
To: LSIM SAFETY INSTITUTE CORPORATION
Reel/Frame 066747/0640 →
CHANGE OF NAME & ADDRESS Recorded Mar 6, 2024
From: LSIM SAFETY INSTITUTE CORPORATION
To: MEDIFORD CORPORATION
Reel/Frame 066747/0706 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2020
From: KAKINUMA, HIDEAKI; SHIMADA, YUKIKO; INOUE, HIROAKI; MORIKAWA, TAKASHI
To: LSI MEDIENCE CORPORATION
Reel/Frame 052667/0595 →
Priority Claims (1)
JP JP2017-051612 · Mar 16, 2017 · national
Continuity (1)
Related Publication 20200071676A1 · Mar 5, 2020